St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Association of British Neurologists : revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

Thumbnail
View/Open
Scolding_2016_ABN_PractNeuro_AAM.pdf (7.618Mb)
Date
08/2015
Author
Scolding, Neil
Barnes, David
Cader, Sarah
Chataway, Jeremy
Chaudhuri, Abhijit
Coles, Alasdair
Giovannoni, Gavin
Miller, David
Rashid, Waqar
Schmierer, Klaus
Shehu, Abdullah
Silber, Eli
Young, Carolyn
Zajicek, John
Keywords
Disease Management
Drug Prescriptions
Great Britain
Guidelines as Topic
Humans
Multiple Sclerosis
Physicians
RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
NDAS
Metadata
Show full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Abstract
In June 1999, the Association of British Neurologists (ABN) first published guidelines for the use of the licensed multiple sclerosis (MS) disease-modifying treatments (at that time β-interferon and glatiramer acetate). The guidelines were revised in 2001 and have been periodically updated since then. In 2002, following the negative assessment of these treatments by the National Institute for Health and Care Excellence (NICE), the MS risk-sharing scheme started, in which patients eligible according to the 2001 ABN guidelines were provided with treatment funded through the UK National Health Service (NHS), and monitored annually for up to 10 years.1 Recruitment to the risk-sharing scheme cohort is complete. Pending a future final evaluation, the UK Department of Health's instruction to NHS funders remains in place: that patients who fulfil the ABN criteria should continue to receive treatment funded through the NHS. The British neurological community has fully accepted the risk-sharing scheme for prescribing β-interferon and glatiramer acetate. Approximately 70 ‘treating centres’ have recruited >5000 patients between 2002 and 2005, and these have been monitored annually for 10 years; many more patients have received these treatments since 2005. The ABN published revised guidelines in 2007, and then again in 2009, following the licensing of natalizumab and mitoxantrone. This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use. These guidelines will require future revision as other treatments receive approval (eg, daclizumab and ocrelizumab): we suggest they are reviewed after an interval of no longer than 12 months. The guideline is not intended to provide a complete description of the possible complications and monitoring of disease-modifying treatments in MS; we refer prescribing neurologists to the relevant summaries of product characteristics.
Citation
Scolding , N , Barnes , D , Cader , S , Chataway , J , Chaudhuri , A , Coles , A , Giovannoni , G , Miller , D , Rashid , W , Schmierer , K , Shehu , A , Silber , E , Young , C & Zajicek , J 2015 , ' Association of British Neurologists : revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis ' , Practical Neurology , vol. 15 , no. 4 , pp. 273-279 . https://doi.org/10.1136/practneurol-2015-001139
Publication
Practical Neurology
Status
Peer reviewed
DOI
https://doi.org/10.1136/practneurol-2015-001139
ISSN
1474-7758
Type
Journal article
Rights
© 2015, the Author(s). This work is made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at pn.bmj.com / https://dx.doi.org/10.1136/practneurol-2015-001139
Collections
  • University of St Andrews Research
URL
http://www.scopus.com/inward/record.url?scp=84937402267&partnerID=8YFLogxK
URI
http://hdl.handle.net/10023/8952

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter